

Michel Azizi

List of Publications by Citations

Source: <https://exaly.com/author-pdf/11829025/michel-azizi-publications-by-citations.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

103
papers

9,997
citations

38
h-index

99
g-index

116
ext. papers

13,433
ext. citations

7.4
avg, IF

5.56
L-index

#	Paper	IF	Citations
103	2018 ESC/ESH Guidelines for the management of arterial hypertension. <i>European Heart Journal</i> , 2018 , 39, 3021-3104	9.5	3698
102	2018 ESC/ESH Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension. <i>Journal of Hypertension</i> , 2018 , 36, 1733-1734	1.9	1262
101	2018 Practice Guidelines for the management of arterial hypertension of the European Society of Hypertension and the European Society of Cardiology: ESH/ESC Task Force for the Management of Arterial Hypertension. <i>Journal of Hypertension</i> , 2018 , 36, 2284-2309	1.9	372
100	Optimum and stepped care standardised antihypertensive treatment with or without renal denervation for resistant hypertension (DENERHTN): a multicentre, open-label, randomised controlled trial. <i>Lancet, The</i> , 2015 , 385, 1957-65	4.0	356
99	Endovascular ultrasound renal denervation to treat hypertension (RADIANCE-HTN SOLO): a multicentre, international, single-blind, randomised, sham-controlled trial. <i>Lancet, The</i> , 2018 , 391, 2335-2345	4.0	301
98	Pharmacologic demonstration of the synergistic effects of a combination of the renin inhibitor aliskiren and the AT1 receptor antagonist valsartan on the angiotensin II-renin feedback interruption. <i>Journal of the American Society of Nephrology: JASN</i> , 2004 , 15, 3126-33	12.7	207
97	Hypertension, the renin-angiotensin system, and the risk of lower respiratory tract infections and lung injury: implications for COVID-19. <i>Cardiovascular Research</i> , 2020 , 116, 1688-1699	9.9	200
96	Renin inhibition with aliskiren: where are we now, and where are we going?. <i>Journal of Hypertension</i> , 2006 , 24, 243-56	1.9	195
95	Aliskiren, an orally effective renin inhibitor, provides antihypertensive efficacy alone and in combination with valsartan. <i>American Journal of Hypertension</i> , 2007 , 20, 11-20	2.3	173
94	Combined blockade of the renin-angiotensin system with angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor antagonists. <i>Circulation</i> , 2004 , 109, 2492-9	16.7	165
93	Home blood-pressure monitoring in patients receiving sunitinib. <i>New England Journal of Medicine</i> , 2008 , 358, 95-7	59.2	150
92	Additive effects of combined angiotensin-converting enzyme inhibition and angiotensin II antagonism on blood pressure and renin release in sodium-depleted normotensives. <i>Circulation</i> , 1995 , 92, 825-34	16.7	148
91	2018 Practice Guidelines for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension. <i>Blood Pressure</i> , 2018 , 27, 314-340	1.7	132
90	European consensus on the diagnosis and management of fibromuscular dysplasia. <i>Journal of Hypertension</i> , 2014 , 32, 1367-78	1.9	123
89	First International Consensus on the diagnosis and management of fibromuscular dysplasia. <i>Vascular Medicine</i> , 2019 , 24, 164-189	3.3	121
88	The double challenge of resistant hypertension and chronic kidney disease. <i>Lancet, The</i> , 2015 , 386, 1588-98	4.8	108
87	Reciprocal regulation of plasma apelin and vasopressin by osmotic stimuli. <i>Journal of the American Society of Nephrology: JASN</i> , 2008 , 19, 1015-24	12.7	100

86	Evaluation of Adherence Should Become an Integral Part of Assessment of Patients With Apparently Treatment-Resistant Hypertension. <i>Hypertension</i> , 2016 , 68, 297-306	8.5	99
85	PHACTR1 Is a Genetic Susceptibility Locus for Fibromuscular Dysplasia Supporting Its Complex Genetic Pattern of Inheritance. <i>PLoS Genetics</i> , 2016 , 12, e1006367	6	99
84	Adherence to Antihypertensive Treatment and the Blood Pressure-Lowering Effects of Renal Denervation in the Renal Denervation for Hypertension (DENERHTN) Trial. <i>Circulation</i> , 2016 , 134, 847-57	16.7	98
83	Sequential nephron blockade versus sequential renin-angiotensin system blockade in resistant hypertension: a prospective, randomized, open blinded endpoint study. <i>Journal of Hypertension</i> , 2012 , 30, 1656-64	1.9	88
82	Additive effects of losartan and enalapril on blood pressure and plasma active renin. <i>Hypertension</i> , 1997 , 29, 634-40	8.5	83
81	Association between 2 angiographic subtypes of renal artery fibromuscular dysplasia and clinical characteristics. <i>Circulation</i> , 2012 , 126, 3062-9	16.7	78
80	SAT-012 Urinary Aldosterone Assay Using LC-MS/MS Could Improve Primary Aldosteronism Screening. <i>Journal of the Endocrine Society</i> , 2019 , 3,	0.4	78
79	High Prevalence of Multiple Arterial Bed Lesions in Patients With Fibromuscular Dysplasia: The ARCADIA Registry (Assessment of Renal and Cervical Artery Dysplasia). <i>Hypertension</i> , 2017 , 70, 652-658	8.5	76
78	Pilot study of combined blockade of the renin-angiotensin system in essential hypertensive patients. <i>Journal of Hypertension</i> , 2000 , 18, 1139-47	1.9	61
77	Six-Month Results of Treatment-Blinded Medication Titration for Hypertension Control Following Randomization to Endovascular Ultrasound Renal Denervation or a Sham Procedure in the RADIANCE-HTN SOLO Trial. <i>Circulation</i> , 2019 ,	16.7	58
76	Drug adherence in hypertension: from methodological issues to cardiovascular outcomes. <i>Journal of Hypertension</i> , 2017 , 35, 1133-1144	1.9	55
75	Meta-analysis of randomized controlled trials of renal denervation in treatment-resistant hypertension. <i>Blood Pressure</i> , 2015 , 24, 263-74	1.7	51
74	Hormonal and hemodynamic effects of aliskiren and valsartan and their combination in sodium-replete normotensive individuals. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2007 , 2, 947-55	6.9	50
73	Ultrasound renal denervation for hypertension resistant to a triple medication pill (RADIANCE-HTN TRIO): a randomised, multicentre, single-blind, sham-controlled trial. <i>Lancet, The</i> , 2021 , 397, 2476-2486	4 ⁰	47
72	Managing cardiovascular and renal risk: the potential of direct renin inhibition. <i>JRAAS - Journal of the Renin-Angiotensin-Aldosterone System</i> , 2009 , 10, 65-76	3	46
71	Renal denervation with a percutaneous bipolar radiofrequency balloon catheter in patients with resistant hypertension: 6-month results from the REDUCE-HTN clinical study. <i>EuroIntervention</i> , 2015 , 10, 1213-20	3.1	46
70	Association of smoking with phenotype at diagnosis and vascular interventions in patients with renal artery fibromuscular dysplasia. <i>Hypertension</i> , 2013 , 61, 1227-32	8.5	43
69	A multinational clinical approach to assessing the effectiveness of catheter-based ultrasound renal denervation: The RADIANCE-HTN and REQUIRE clinical study designs. <i>American Heart Journal</i> , 2018 , 195, 115-129	4.9	39

68	Conformational changes in prorenin during renin inhibition in vitro and in vivo. <i>Journal of Hypertension</i> , 2006 , 24, 529-34	1.9	36
67	Integrating drug pharmacokinetics for phenotyping individual renin response to angiotensin II blockade in humans. <i>Hypertension</i> , 2004 , 43, 785-90	8.5	35
66	Device-based therapies for arterial hypertension. <i>Nature Reviews Cardiology</i> , 2020 , 17, 614-628	14.8	35
65	Renal Denervation for Treatment of Hypertension: a Second Start and New Challenges. <i>Current Hypertension Reports</i> , 2016 , 18, 6	4.7	28
64	Emerging Drug Classes and Their Potential Use in Hypertension. <i>Hypertension</i> , 2019 , 74, 1075-1083	8.5	26
63	European Society of Hypertension position paper on renal denervation 2018. <i>Journal of Hypertension</i> , 2018 , 36, 2042-2048	1.9	24
62	Haemodynamic effects of dual blockade of the renin-angiotensin system in spontaneously hypertensive rats: influence of salt. <i>Journal of Hypertension</i> , 2004 , 22, 619-27	1.9	22
61	Renin inhibitors and cardiovascular and renal protection: an endless quest?. <i>Cardiovascular Drugs and Therapy</i> , 2013 , 27, 145-53	3.9	21
60	Renin inhibition. <i>Current Opinion in Nephrology and Hypertension</i> , 2006 , 15, 505-10	3.5	21
59	Cause of renal infarction: a retrospective analysis of 186 consecutive cases. <i>Journal of Hypertension</i> , 2018 , 36, 634-640	1.9	20
58	Renal artery stenosis following renal denervation: a matter of concern. <i>Journal of Hypertension</i> , 2014 , 32, 2101-5	1.9	20
57	Twenty-Four-Hour Blood Pressure Monitoring to Predict and Assess Impact of Renal Denervation: The DENERHTN Study (Renal Denervation for Hypertension). <i>Hypertension</i> , 2017 , 69, 494-500	8.5	19
56	12-Month Results From the Unblinded Phase of the RADIANCE-HTN SOLO Trial of Ultrasound Renal Denervation. <i>JACC: Cardiovascular Interventions</i> , 2020 , 13, 2922-2933	5	19
55	True antihypertensive efficacy of sequential nephron blockade in patients with resistant hypertension and confirmed medication adherence. <i>Journal of Hypertension</i> , 2015 , 33, 2526-33	1.9	19
54	Abdominal Aortic Calcifications Influences the Systemic and Renal Hemodynamic Response to Renal Denervation in the DENERHTN (Renal Denervation for Hypertension) Trial. <i>Journal of the American Heart Association</i> , 2017 , 6,	6	18
53	Salvage therapy with bevacizumab-sunitinib combination after failure of sunitinib alone for metastatic renal cell carcinoma: a case series. <i>European Urology</i> , 2009 , 56, 207-11; quiz 211	10.2	18
52	Physiologic consequences of vasopeptidase inhibition in humans: effect of sodium intake. <i>Journal of the American Society of Nephrology: JASN</i> , 2002 , 13, 2454-63	12.7	17
51	Design considerations for clinical trials of autonomic modulation therapies targeting hypertension and heart failure. <i>Hypertension</i> , 2015 , 65, 5-15	8.5	16

50	Pharmacokinetics and pharmacodynamics of the vasopeptidase inhibitor AVE7688 in humans. <i>Clinical Pharmacology and Therapeutics</i> , 2006 , 79, 49-61	6.1	16
49	Direct renin inhibition: clinical pharmacology. <i>Journal of Molecular Medicine</i> , 2008 , 86, 647-54	5.5	15
48	Eligibility for renal denervation: anatomical classification and results in essential resistant hypertension. <i>CardioVascular and Interventional Radiology</i> , 2015 , 38, 79-87	2.7	14
47	Dual renin-angiotensin system blockade restores blood pressure-renin dependency in individuals with low renin concentrations. <i>Journal of Hypertension</i> , 2003 , 21, 1887-95	1.9	14
46	Pharmacokinetic-pharmacodynamic interactions of candesartan cilexetil and losartan. <i>Journal of Hypertension</i> , 1999 , 17, 561-8	1.9	14
45	Resistant Hypertension and Atherosclerotic Renal Artery Stenosis: Effects of Angioplasty on Ambulatory Blood Pressure. A Retrospective Uncontrolled Single-Center Study. <i>Hypertension</i> , 2019 , 74, 1516-1523	8.5	13
44	Greater efficacy of aldosterone blockade and diuretic reinforcement vs. dual renin-angiotensin blockade for left ventricular mass regression in patients with resistant hypertension. <i>Journal of Hypertension</i> , 2014 , 32, 2038-44; discussion 2044	1.9	13
43	Renin inhibition with aliskiren. <i>Clinical and Experimental Pharmacology and Physiology</i> , 2008 , 35, 426-30	3	13
42	SPARTE Study: Normalization of Arterial Stiffness and Cardiovascular Events in Patients With Hypertension at Medium to Very High Risk. <i>Hypertension</i> , 2021 , 78, 983-995	8.5	13
41	Rare loss-of-function mutations of PTGIR are enriched in fibromuscular dysplasia. <i>Cardiovascular Research</i> , 2021 , 117, 1154-1165	9.9	10
40	Clinic Versus Ambulatory Blood Pressure in Resistant Hypertension: Impact of Antihypertensive Medication Nonadherence: A Post Hoc Analysis the DENERHTN Study. <i>Hypertension</i> , 2019 , 74, 1096-1103	8.5	8
39	Effect of contrasted sodium diets on the pharmacokinetics and pharmacodynamic effects of renin-angiotensin system blockers. <i>Hypertension</i> , 2013 , 61, 1239-45	8.5	8
38	Rationale for combining blockers of the renin-angiotensin system. <i>Seminars in Nephrology</i> , 2007 , 27, 544-54	4.8	8
37	Aldosterone-Related Myocardial Extracellular Matrix Expansion in Hypertension in Humans: A Proof-of-Concept Study by Cardiac Magnetic Resonance. <i>JACC: Cardiovascular Imaging</i> , 2020 , 13, 2149-2159	8.4	7
36	Usefulness of Magnetic Resonance Imaging in the Diagnosis of Juxtaglomerular Cell Tumors: A Report of 10 Cases and Review of the Literature. <i>American Journal of Kidney Diseases</i> , 2019 , 73, 566-571	7.4	7
35	Impaired atrioventricular transport in patients with transposition of the great arteries palliated by atrial switch and preserved systolic right ventricular function: A magnetic resonance imaging study. <i>Congenital Heart Disease</i> , 2017 , 12, 458-466	3.1	6
34	How to perform a cost-effectiveness analysis with surrogate endpoint: renal denervation in patients with resistant hypertension (DENERHTN) trial as an example. <i>Blood Pressure</i> , 2018 , 27, 66-72	1.7	6
33	Catheter-based renal denervation for treatment of hypertension. <i>Lancet, The</i> , 2017 , 390, 2124-2126	4.0	6

32	Nonadherence in Hypertension: How to Develop and Implement Chemical Adherence Testing. <i>Hypertension</i> , 2022 , 79, 12-23	8.5	6
31	Ambulatory Blood Pressure Monitoring to Predict Response to Renal Denervation: A Post Hoc Analysis of the RADIANCE-HTN SOLO Study. <i>Hypertension</i> , 2021 , 77, 529-536	8.5	6
30	Transcriptome Analysis of Human Reninomas as an Approach to Understanding Juxtaglomerular Cell Biology. <i>Hypertension</i> , 2017 , 69, 1145-1155	8.5	5
29	Design of renal denervation studies not confounded by antihypertensive drugs. <i>Journal of the American Society of Hypertension</i> , 2015 , 9, 337-40		5
28	Home blood pressure monitoring and e-Health: investigation of patients' experience with the Hy-Result system. <i>Blood Pressure Monitoring</i> , 2020 , 25, 155-161	1.3	5
27	Clinical characteristics, antihypertensive medication use and blood pressure control among patients with treatment-resistant hypertension: the Survey of Patients with treatment Resistant hyperTension study. <i>Journal of Hypertension</i> , 2019 , 37, 2216-2224	1.9	5
26	Poor adherence to medication and salt restriction as a barrier to reaching blood pressure control in patients with hypertension: Cross-sectional study from 12 sub-Saharan countries. <i>Archives of Cardiovascular Diseases</i> , 2020 , 113, 433-442	2.7	4
25	Aldosterone receptor antagonists. <i>Annales D'Endocrinologie</i> , 2021 , 82, 179-181	1.7	4
24	Drug-resistant hypertension in primary aldosteronism patients undergoing adrenal vein sampling: the AVIS-2-RH study. <i>European Journal of Preventive Cardiology</i> , 2021 ,	3.9	4
23	Genetic investigation of fibromuscular dysplasia identifies risk loci and shared genetics with common cardiovascular diseases. <i>Nature Communications</i> , 2021 , 12, 6031	17.4	3
22	Predictors of blood pressure response to ultrasound renal denervation in the RADIANCE-HTN SOLO study. <i>Journal of Human Hypertension</i> , 2021 ,	2.6	3
21	P-glycoprotein influences urinary excretion of aldosterone in healthy individuals. <i>Journal of Hypertension</i> , 2019 , 37, 2225-2231	1.9	3
20	Clinical Trial Design Principles and Outcomes Definitions for Device-Based Therapies for Hypertension: A Consensus Document From the Hypertension Academic Research Consortium.. <i>Circulation</i> , 2022 , 145, 847-863	16.7	3
19	Sequential nephron blockade with combined diuretics improves diastolic function in patients with resistant hypertension. <i>ESC Heart Failure</i> , 2020 , 7, 2561-2571	3.7	2
18	Will SPYRAL HTN-ON MED change my practice? SPYRAL HTN-ON MED: a prospective, randomised, sham-controlled trial on renal denervation in the presence of antihypertensive medications. <i>EuroIntervention</i> , 2018 , 14, e598-e602	3.1	2
17	Will SPYRAL HTN-OFF MED change my practice? SPYRAL HTN-OFF MED: a prospective, randomised, sham-controlled trial on renal denervation in the absence of antihypertensive medications. <i>EuroIntervention</i> , 2018 , 14, e603-e606	3.1	2
16	Current progress in clinical, molecular, and genetic aspects of adult fibromuscular dysplasia. <i>Cardiovascular Research</i> , 2021 ,	9.9	2
15	Beyond Atherosclerosis and Fibromuscular Dysplasia: Rare Causes of Renovascular Hypertension. <i>Hypertension</i> , 2021 , 78, 898-911	8.5	2

14	Renal denervation for resistant hypertension - AuthorsReply. <i>Lancet, The</i> , 2015 , 386, 1240	4.0	1
13	Antihypertensive strategies and hypertension control in Sub-Saharan Africa. <i>European Journal of Preventive Cardiology</i> , 2021 , 28, e21-e25	3.9	1
12	Renin-angiotensin system blockade: to what extent?. <i>Journal of Hypertension</i> , 2004 , 22, 459-62	1.9	1
11	Renal artery variations in patients with mild-to-moderate hypertension from the RADIANCE-HTN SOLO trial. <i>Cardiovascular Revascularization Medicine</i> , 2021 ,	1.6	1
10	Use of traditional medicine and control of hypertension in 12 African countries. <i>BMJ Global Health</i> , 2022 , 7, e008138	6.6	1
9	Using social media to recruit study participants for a randomized trial for hypertension. <i>European Heart Journal Digital Health</i> , 2020 , 1, 71-74	2.3	0
8	Blood pressure-lowering medicines implemented in 12 African countries: the cross-sectional multinational EIGHT study. <i>BMJ Open</i> , 2021 , 11, e049632	3	0
7	Resistant Hypertension 2018 , 398-408		0
6	Drug-Induced Hypertension. <i>Updates in Hypertension and Cardiovascular Protection</i> , 2020 , 159-166	0.1	
5	Effets vasculaires et r�aux des m�dicaments anti-angiog�niques : recommandations fran�aises pour la pratique. <i>Sang Thrombose Vaisseaux</i> , 2009 , 21, 151-166	3	
4	Highlights from International Congress : The XI Forum on the Renin-Angiotensin System, Capri, Italy, 11-12 April, 2008. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2008 , 15, 91-104	2.9	
3	Drug Adherence in Resistant Hypertension. <i>Updates in Hypertension and Cardiovascular Protection</i> , 2018 , 185-197	0.1	
2	La recherche en hypertension art�rielle en France. <i>Bulletin De L'Academie Nationale De Medecine</i> , 2018 , 202, 1571-1579	0.1	
1	Blocage combin� du syst�me r�ine angiotensine. <i>Bulletin De L'Academie Nationale De Medecine</i> , 2014 , 198, 351-362	0.1	